Catalyst Event
Takeda Pharmaceutical Co Ltd (TAK) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/23/2026, 12:00:00 AM
The U.S. Supreme Court allowed a multibillion-dollar racketeering lawsuit to proceed against Takeda and Eli Lilly concerning allegations they marketed the diabetes drug Actos without disclosing its link to bladder cancer, scheduled. High impact expected due to potential for massive legal liabilities and reputational damage.
Korean Translation
미국 대법원이 다케다와 일라이 릴리를 상대로 당뇨병 치료제 액토스의 방광암 위험성을 은폐하고 판매했다는 혐의로 제기된 수십억 달러 규모의 리코법 소송 진행을 허용할 것으로 예정됨. 막대한 법적 배상금 및 기업 평판 훼손 가능성으로 인해 높은 시장 영향이 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Q1 2026 earnings release is scheduled. Impact is estimated to be low as it is a routine quarterly announcement.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva announced it will release its financial results for the first quarter of 2026 on April 29, 2026, scheduled. Low price impact expected for this routine announcement.
4/29/2026, 12:00:00 AM